The incidence of any grades of ir-pneumonitis varies depending on therapy, with combined therapies having higher rates (6.5–10%) compared to anti-PD1, anti-PDL1, and anti-CTLA-4 monotherapies (4%, 2%, and <1%, respectively) [26,27,31,32,33]. The gene discussed is CTLA4; the disease is pneumonitis.